New analyses on retatrutide, a dual stimulant for GLP-1 and GIP, suggest promising findings in treating excess body fat and type 2 glucose intolerance. Preliminary data from clinical trials show substantial diminutions in body weight and enhanced glucose control. Ongoing exploration is directed on long-term harmlessness and efficacy, as well as … Read More